Mirae Asset Global Investments Co. Ltd. Sells 10,260 Shares of Repligen Corporation $RGEN

Mirae Asset Global Investments Co. Ltd. cut its holdings in Repligen Corporation (NASDAQ:RGEN) by 34.8% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 19,262 shares of the biotechnology company’s stock after selling 10,260 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Repligen were worth $2,575,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Brown Capital Management LLC raised its stake in shares of Repligen by 16.3% in the second quarter. Brown Capital Management LLC now owns 1,005,276 shares of the biotechnology company’s stock worth $125,036,000 after purchasing an additional 141,241 shares during the last quarter. Stephens Investment Management Group LLC increased its holdings in Repligen by 14.4% in the 3rd quarter. Stephens Investment Management Group LLC now owns 598,356 shares of the biotechnology company’s stock worth $79,982,000 after buying an additional 75,509 shares in the last quarter. Geneva Capital Management LLC raised its position in Repligen by 239.6% in the 2nd quarter. Geneva Capital Management LLC now owns 487,534 shares of the biotechnology company’s stock worth $60,639,000 after buying an additional 343,991 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its position in Repligen by 3,219.3% in the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 413,425 shares of the biotechnology company’s stock worth $51,422,000 after buying an additional 400,970 shares during the last quarter. Finally, Blue Whale Capital LLP bought a new position in Repligen during the 2nd quarter valued at about $35,782,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Repligen

In other news, Director Karen A. Dawes sold 275 shares of the firm’s stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $161.00, for a total value of $44,275.00. Following the transaction, the director owned 91,821 shares of the company’s stock, valued at $14,783,181. This trade represents a 0.30% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO James Bylund sold 2,191 shares of the business’s stock in a transaction that occurred on Tuesday, November 18th. The shares were sold at an average price of $151.21, for a total value of $331,301.11. Following the transaction, the chief operating officer owned 21,520 shares of the company’s stock, valued at approximately $3,254,039.20. This trade represents a 9.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 49,657 shares of company stock valued at $7,721,077 over the last quarter. 1.20% of the stock is currently owned by company insiders.

Repligen Trading Up 1.2%

NASDAQ:RGEN opened at $151.12 on Tuesday. Repligen Corporation has a one year low of $102.96 and a one year high of $175.77. The business has a fifty day moving average price of $164.05 and a 200-day moving average price of $144.43. The firm has a market capitalization of $8.51 billion, a price-to-earnings ratio of 7,559.78, a price-to-earnings-growth ratio of 2.71 and a beta of 1.13. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.36 and a quick ratio of 7.14.

Analysts Set New Price Targets

RGEN has been the subject of a number of research analyst reports. UBS Group lifted their price target on shares of Repligen from $190.00 to $200.00 and gave the stock a “buy” rating in a research note on Friday, January 16th. Wall Street Zen cut shares of Repligen from a “buy” rating to a “hold” rating in a report on Tuesday, November 4th. Wells Fargo & Company boosted their target price on shares of Repligen from $175.00 to $190.00 and gave the company an “overweight” rating in a research note on Monday, December 15th. Jefferies Financial Group set a $160.00 price target on Repligen and gave the stock a “hold” rating in a research note on Tuesday, October 28th. Finally, Evercore ISI upped their price objective on Repligen from $155.00 to $175.00 and gave the company an “outperform” rating in a research report on Tuesday, October 7th. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $179.62.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.